Patrys Initiates Manufacturing and FDA Engagement for Injectable Delirium Treatment RLS-2201
核心洞察
Patrys (搜索) has commenced engineering batch manufacturing of RLS-2201 (搜索) with BioCina (搜索) and initiated FDA regulatory engagement through the expedited 505(b)(2) pathway for delirium (搜索) treatment.
The injectable reformulation of quetiapine targets a significant $2 billion annual market opportunity across intensive care, palliative care, and aged care settings.
Phase 0 first-in-human trials are planned for H2 2026, with the company expecting to finalize Contract Research Organisation selection in Q2 2026.
Patrys (搜索) (ASX: PAB) has launched critical manufacturing and regulatory activities for its RLS-2201 (搜索) delirium (搜索) treatment program, marking a significant advancement in addressing an unmet medical need valued at approximately $2 billion annually. The company has initiated engineering batch manufacturing with BioCina (搜索) and begun FDA regulatory engagement targeting the expedited 505(b)(2) pathway.
Manufacturing Scale-Up Begins
Engineering batch manufacturing of RLS-2201 (搜索) has commenced with BioCina (搜索), representing a crucial step designed to replicate commercial-scale processes. The manufacturing process will support stability testing and generate early clinical material, while setting the stage for future Good Manufacturing Practice (GMP) material production essential for Phase I dosing and process validation.
Strategic FDA Pathway Engagement
US regulatory engagement has begun with Facet Life Sciences (搜索), aimed at preparing for an FDA Investigational New Drug (IND) submission for RLS-2201 (搜索). The regulatory strategy focuses on the FDA 505(b)(2) pathway, which leverages existing safety data from oral quetiapine, potentially accelerating the development timeline.
Phase 0 first-in-human trials are planned for H2 2026, with the company expecting to finalize the selection of a Contract Research Organisation (CRO) in Q2 2026.
Addressing Significant Market Opportunity
The company's injectable reformulation of quetiapine, previously known as AQS and now designated RLS-2201 (搜索), targets a large, unmet medical need across intensive care, palliative care, and aged care settings. Previous investor presentations in January 2026 highlighted the significant market opportunity for delirium (搜索) treatment, estimated at approximately $2 billion annually.
The initiation of manufacturing and regulatory steps signifies a de-risking of the RLS-2201 (搜索) program and adds a value-creating program to Patrys (搜索)' pipeline, presenting potential near-term catalysts.
Leadership and Strategic Direction
Dr Samantha South was appointed Chief Executive Officer in February 2026, bringing extensive experience in translational science and regulatory strategy. Her appointment is expected to accelerate clinical progression and value creation across Patrys (搜索)' expanded pipeline, with her expertise aligning with the company's evolution into a dual-platform, catalyst-driven, clinical-stage entity.
Development Outlook
While these manufacturing and regulatory steps de-risk the program and target a significant market, execution and regulatory success remain contingent on agency feedback and timely completion of manufacturing and CRO timelines. Funding for later-stage trials and commercialization remains a key consideration, along with potential delays in regulatory approval.